Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Multiple Myeloma Clinical Trials

110 recruiting trials for Multiple Myeloma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
110
Total Trials
110
Recruiting Now
7
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 2NCT04731844

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients...

Sponsor: University of RochesterEnrolling: 401 location
RECRUITINGNCT05366881

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer...

Sponsor: Adela, IncEnrolling: 700017 locations
RECRUITINGPhase 1NCT06623630

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti;...

Treatment for relapsed/refractory multiple myeloma continues to evolve with the approval of highly effective anti-BCMA CAR T therapies in recent years. However, despite the high...

Sponsor: Washington University School of MedicineEnrolling: 161 location
RECRUITINGNCT06483139

Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

Objective 1: To test whether treatment with plasma exchange improves renal recovery in patients with light chain cast nephropathy Objective 2: To compare renal outcomes among...

Sponsor: Brigham and Women's HospitalEnrolling: 4501 location
RECRUITINGNCT05283993

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed...

Sponsor: Peking University First HospitalEnrolling: 20001 location
RECRUITINGPhase 2NCT07489534

Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction

The purpose of this study is to determine the efficacy and safety of targeted BCMA CART cells secreting PD1 and interleukin 21 fusion protein immunotherapy for first-line...

Sponsor: Daihong LiuEnrolling: 251 location
RECRUITINGPhase 2NCT05969860

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to...

Sponsor: Mayo ClinicEnrolling: 2202 locations
RECRUITINGNCT02012699

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal...

Sponsor: University of NebraskaEnrolling: 99999920 locations
RECRUITINGNCT07100067

LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma

A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of...

Sponsor: Nanjing Legend Biotech Co.Enrolling: 354 locations
RECRUITINGPhase 2NCT06627751

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients...

This phase II trial studies how well mezigdomide/carfilzomib/dexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of...

Sponsor: Roswell Park Cancer InstituteEnrolling: 281 location
RECRUITINGNCT05745285

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among...

Sponsor: University of MiamiEnrolling: 4003 locations
RECRUITINGPhase 1NCT03633955

Pilot Imaging Study of Leukemia

This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated...

Sponsor: University of OklahomaEnrolling: 603 locations
RECRUITINGPhase 1 / Phase 2NCT05828511

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult...

This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who...

Sponsor: Regeneron PharmaceuticalsEnrolling: 14920 locations
RECRUITINGNCT05620238

Home Treatment With Carfilzomib in Patients With Multiple Myeloma

New treatment regimens with increased efficiency and reduced toxicities are being introduced in the treatment of Multiple Myeloma (MM). As a result, patients can expect increased...

Sponsor: Thomas LundEnrolling: 121 location
RECRUITINGPhase 1NCT05666700

CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular...

This clinical trial will investigate the in vivo trafficking of cilta-cel in extramedullary myeloma using 64Cu Super Paramagnetic Iron Oxide Nanoparticle (64Cu SPION) and Positron...

Sponsor: Peter MacCallum Cancer Centre, AustraliaEnrolling: 101 location
RECRUITINGPhase 1 / Phase 2NCT06644443

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

At present, MM is still an incurable disease in general, and the vast majority of patients will eventually face disease recurrence or progression. Although CAR-T therapy targeting...

Sponsor: Shenzhen University General HospitalEnrolling: 101 location
RECRUITINGPhase 1 / Phase 2NCT06087653

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

Primary Objective • Assess the safety and tolerability of low-dose lenalidomide administered by continuous subcutaneous (SC) infusion (STAR-LLD) in combination with dexamethasone...

Sponsor: Starton Therapeutics, IncEnrolling: 242 locations
RECRUITINGPhase 3NCT07258511

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants...

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

Sponsor: Janssen Research & Development, LLCEnrolling: 40020 locations
RECRUITINGNCT07390071

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

The proposed multimodal telerehabilitation model allows a rehabilitation therapy team to set up individualized rehabilitation plans using a web-based care management portal and...

Sponsor: University of UtahEnrolling: 401 location
RECRUITINGPhase 2NCT07045909

Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

The goal of this clinical trial is to learn if anitocabtagene autoleucel following induction therapy works to treat adult participants with newly diagnosed multiple myeloma. The...

Sponsor: PETHEMA FoundationEnrolling: 3010 locations
RECRUITINGNCT07497165

Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma

Background: Multiple Myeloma remains an incurable hematologic malignancy, and outcomes for relapsed/refractory multiple myeloma (RRMM) remain unsatisfactory despite advances in...

Sponsor: Shanxi Bethune HospitalEnrolling: 481 location
RECRUITINGPhase 3NCT07138209

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in...

The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.

Sponsor: Qilu Pharmaceutical Co., Ltd.Enrolling: 2281 location
RECRUITINGNCT07052916

A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties

Research has shown that music-based activities may help improve brain functions, such as attention, memory, and executive function. Because of this past research, the researchers...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 607 locations
RECRUITINGPhase 2NCT05272826

Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

This study will evaluate efficacy and tolerability of iberdomide, bortezomib, dexamethasone and isatuximab on demand administered in combination for newly diagnosed...

Sponsor: Canadian Myeloma Research GroupEnrolling: 757 locations
RECRUITINGNCT01137643

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future....

Sponsor: UNC Lineberger Comprehensive Cancer CenterEnrolling: 150001 location
RECRUITINGPhase 1NCT05363111

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

This phase I trial tests the safety, side effects, and best dose of actinium Ac 225-DOTA-daratumumab (225Ac-DOTA-daratumumab) in combination with daratumumab and indium In...

Sponsor: City of Hope Medical CenterEnrolling: 151 location
RECRUITINGPhase 1 / Phase 2NCT06911710

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

This study is an open, single-arm, prospective, Phase I/II clinical study using "3+3" dose escalation and dose expansion to investigate the safety, maximum tolerated dose, in vivo...

Sponsor: Tianjin Medical University General HospitalEnrolling: 901 location
RECRUITINGPhase 3NCT06520176

Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

This is a prospective, randomized, two-arm, multicenter, exploratory study aimed at evaluating the efficacy and safety of the combination of etoposide, cytarabine and...

Sponsor: The Affiliated People's Hospital of Ningbo UniversityEnrolling: 9916 locations
RECRUITINGPhase 2NCT07106736

MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma

This is a prospective, single-center, clinical study to evaluate the efficacy and safety of a fully immunotherapy-based strategy guided by MRD-driven dynamic risk stratification...

Sponsor: Institute of Hematology & Blood Diseases Hospital, ChinaEnrolling: 601 location
RECRUITINGNCT06698887

A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple...

The purpose of this study is to monitor the long-term safety of participants who received idecabtagene vicleucel treatment as part of the KarMMa-9 (CA089-1043) Phase 3 clinical...

Sponsor: Bristol-Myers SquibbEnrolling: 155 locations
RECRUITINGNCT06690593

Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy

This is an observational case-control study, aiming to systematically analyze the gut microbiome characteristics of patients with monoclonal gammopathy of undetermined...

Sponsor: Zhujiang HospitalEnrolling: 29901 location
RECRUITINGNCT05996367

Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma

Multiple myeloma is a plasma cell neoplasm that can cause painful bone lesions. The main treatment for these lesions and pain control is radiotherapy, usually in daily fractions....

Sponsor: Instituto do Cancer do Estado de São PauloEnrolling: 501 location
RECRUITINGNCT05706766

Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

The goal of this research study is to investigate whether a virtual, home-based, prehabilitation aerobic and resistance exercise (PARE) training program implemented 8 weeks prior...

Sponsor: Dana-Farber Cancer InstituteEnrolling: 302 locations
RECRUITINGNCT06908629

Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors

The goal of this screening study is to determine the feasibility of completing a social needs screening tool in participants who have a past or current cancer diagnosis and reside...

Sponsor: Barbara Ann Karmanos Cancer InstituteEnrolling: 1201 location
RECRUITINGPhase 1 / Phase 2NCT05714839

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as...

The study consists of three parts: * Part 1 The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent...

Sponsor: GlaxoSmithKlineEnrolling: 15320 locations
RECRUITINGNCT05011045

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 1001 location
RECRUITINGPhase 1 / Phase 2NCT07181941

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class...

This phase I/II trial evaluates the safety and feasibility of early, response-based dose reduction of linvoseltamab in the treatment of patients multiple myeloma that has come...

Sponsor: Fred Hutchinson Cancer CenterEnrolling: 301 location
RECRUITINGPhase 2NCT04558931

Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma

Prospective, single center, randomized, open label, parallel group, 2-arm study assessing the clinical benefit in term of enhancement of overall response rate of Isatuximab in...

Sponsor: Karolinska InstitutetEnrolling: 621 location
RECRUITINGPhase 1NCT03017820

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in...

This phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and combinations of ipilimumab, nivolumab, and cemiplimab...

Sponsor: Mayo ClinicEnrolling: 1272 locations
RECRUITINGPhase 1 / Phase 2NCT06892522

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma...

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause...

Sponsor: AbbVieEnrolling: 44020 locations
RECRUITINGPhase 3NCT06187441

FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With...

In the Netherlands, the standard treatment for multiple myeloma is a combination of different medicines named daratumumab-lenalidomide-dexamethasone, abbreviated as Dara-Rd. In...

Sponsor: Stichting Hemato-Oncologie voor Volwassenen NederlandEnrolling: 59920 locations
RECRUITINGPhase 2NCT06758375

Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients

This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma...

Sponsor: Hospital Universitario Dr. Jose E. GonzalezEnrolling: 101 location
RECRUITINGNCT07180992

Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma

Tumoral micro-environment in malignant haematological diseases, notably in multiple myeloma, is active on plasma cells survival and proliferation. Monocytosis and monocytes typing...

Sponsor: Centre Hospitalier Universitaire, AmiensEnrolling: 251 location
RECRUITINGPhase 2NCT06483100

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease...

Sponsor: Washington University School of MedicineEnrolling: 651 location
RECRUITINGPhase 2 / Phase 3NCT07202052

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

This is an adaptive platform study to find out how safe and effective different strategies are in comparison to each other, for preventing infection in patients with blood...

Sponsor: Monash UniversityEnrolling: 9003 locations
RECRUITINGPhase 1 / Phase 2NCT07477912

Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma

The mail purpose of this study is to estimate the safety and the efficacy of anti-BCMA CAR- T cell immunotherapy for adults with relapsed or refractory multiple myeloma

Sponsor: Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyEnrolling: 301 location
RECRUITINGPhase 1 / Phase 2NCT06536413

ATRA and Carfilzomib in Plasma Cell Myeloma Patients

This is a Phase IB/II trial that will investigate the safety, tolerability and efficacy of combination therapy using All-Trans Retinoic Acid (ATRA) with Carfilzomib based...

Sponsor: The Methodist Hospital Research InstituteEnrolling: 421 location
RECRUITINGNCT03858205

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high...

Sponsor: University of Southern CaliforniaEnrolling: 1009 locations
RECRUITINGNCT06697483

Risk Stratification and MRD-driven Maintenance for MM After ASCT

This study evaluates the maintenance strategy based on risk stratification and MRD status after stem cell transplantation. This is a single-arm, multicenter, prospective study....

Sponsor: Peking University People's HospitalEnrolling: 1004 locations
RECRUITINGPhase 1NCT06484777

A Clinical Study of SHR-9539 in Patients With Multiple Myeloma

This study is a multicenter, open-label, dose-escalation/dose-expansion clinical Phase I trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics,...

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling: 1381 location

Showing 50 of 110 trials.Search all Multiple Myeloma trials

Frequently Asked Questions

There are currently 110 clinical trials for Multiple Myeloma, with 110 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Multiple Myeloma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 7 Phase 3 trials for Multiple Myeloma, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.